Has Jason Gaglia, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,430,904 in general payments to Jason Gaglia, MD across 68 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jason Gaglia, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jason Gaglia, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jason Gaglia, MD

Endocrinology, Diabetes & Metabolism · Boston, MANPI 1023098605

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $2,430,539 of the $2,430,904 with a category attached, or 100.0%. Vertex accounts for 99.7% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2021 at $593,454 and has fallen 99.6% since, to $2,130 in 2025. Among endocrinology, diabetes & metabolism clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,430,904in general payments, 2019–2025

Across 68 payments — averaging $35,749 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Vertex$2.4M
Regeneron Healthcare Solutions, Inc.$3K
AstraZeneca$2K
Current Health, Inc.$2K
Ascensia Diabetes Care US Inc.$490
Sanofi$250
plus $115 from 2 others

$84,961in research payments, 2019–2025

Across 17 payments — averaging $4997.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Dompe Farmaceutici S.p.a.$35K
Novo Nordisk AS$27K
Sanofi$14K
Janssen Research & Development, LLC$10K

What the payments were for

Consulting fees$2,430,539100%
Grants$2500%
Food & beverage$1150%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Vertex	57	$2,423,815
Regeneron Healthcare Solutions, Inc.	1	$2,555
AstraZeneca	1	$1,880
Current Health, Inc.	4	$1,800
Ascensia Diabetes Care US Inc.	1	$490
Sanofi	1	$250
Sanofi-aventis U.S. LLC	1	$59
Abbott	2	$56

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

EYLEA$2,555
EVERSENSE E3 SENSOR KIT - RETAIL$490

How this compares

$2,430,904 in reported general payments places this provider in the 95th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.

See all endocrinology, diabetes & metabolism providers in Massachusetts →

Medicare billing

Part B allowed, 2024

$5,729

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
MounjaroTirzepatide	32	$50,854
OzempicSemaglutide	13	$20,245
JardianceEmpagliflozin	13	$19,012
JanuviaSitagliptin Phosphate	12	$13,419
Tresiba Flextouch U-100Insulin Degludec	15	$11,987
Nano 2nd Gen Pen NeedlePen Needle, Diabetic	12	$1,999
Lantus SolostarInsulin Glargine,hum.Rec.Anlog	15	$1,716
Metformin Hcl ErMetformin Hcl	34	$419
Levothyroxine Sodium	15	$183
Glimepiride	14	$142
Rosuvastatin Calcium	11	$107

Paid to pharmacies, not to this prescriber.

Other endocrinology, diabetes & metabolism in Boston

Vanita ArodaBoston$482K
Michael RosenblattBoston$447K
Steven RussellBoston$445K
Beverly BillerBoston$346K
Christos MantzorosBoston$243K
Augusto Caballero-RoblesBoston$150K
Osama HamdyBoston$117K
Barbara KahnBoston$105K
Naomi FisherBoston$79K
Andrea CovielloBoston$67K

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →